Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,563 recalls, newest first

Class II · Moderate risk

Robafen DM Syrup

cGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

Terminated Microbial contamination Torrent Pharma Inc D-1351-2019
Class II · Moderate risk

Robafen AC Oral Solution

cGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

Terminated Microbial contamination Torrent Pharma Inc D-1350-2019
Class II · Moderate risk

Allergy Liquid Antihistamine

cGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

Terminated Microbial contamination Torrent Pharma Inc D-1347-2019
Class II · Moderate risk

RisperiDONE Oral Solution

cGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

Terminated Microbial contamination Torrent Pharma Inc NDC 13668-589-06 D-1345-2019
Class II · Moderate risk

Amitiza (lubiprostone)

Labeling: Label mix-up. Amitiza 8 mcg capsules are being recalled because 24 mcg capsules were found in a 8 mcg trade 60 ct. bottle. Amitiza 24 mcg capsules are being recalled because a sealed 60 ct. bottle contained only 8 mcg capsules, this incident is being considered as a labeling mix-up issue.

Terminated Labeling / mix-up Mallinckrodt Pharmaceuticals NDC 64764-240-60 D-1295-2019
Class II · Moderate risk

Amitiza (lubiprostone)

Labeling: Label mix-up. Amitiza 8 mcg capsules are being recalled because 24 mcg capsules were found in a 8 mcg trade 60 ct. bottle. Amitiza 24 mcg capsules are being recalled because a sealed 60 ct. bottle contained only 8 mcg capsules, this incident is being considered as a labeling mix-up issue.

Terminated Labeling / mix-up Mallinckrodt Pharmaceuticals NDC 64764-080-60 D-1294-2019
Class I · High risk

Promacta (eltrombopag)

Cross Contamination with Other Products: product is being recalled due to possible cross-contamination with peanut flour.

Terminated Cross-contamination Novartis Pharmaceuticals Corp. NDC 0078-0972-61 D-1309-2019
Class II · Moderate risk

Anastrozole Tablets

GMP Deviations: Potential cross contamination due to cleaning procedure failure.

Terminated Cross-contamination American Health Packaging NDC 68001-155-04 D-1467-2019
Class II · Moderate risk

Anastrozole Tablets

GMP Deviations: Potential cross contamination due to cleaning procedure failure.

Terminated Cross-contamination American Health Packaging NDC 60687-112-21 D-1394-2019
Class II · Moderate risk

MethylPREDNISolone Tablets

CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

Terminated Cross-contamination Zydus Pharmaceuticals USA Inc NDC 68382-917-11 D-1453-2019
Class II · Moderate risk

MethylPREDNISolone Tablets

CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

Terminated Cross-contamination Zydus Pharmaceuticals USA Inc NDC 68382-919-11 D-1451-2019
Class II · Moderate risk

MethylPREDNISolone Tablets

CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

Terminated Cross-contamination Zydus Pharmaceuticals USA Inc NDC 68382-918-18 D-1450-2019
Class II · Moderate risk

MethylPREDNISolone Tablets

CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

Terminated Cross-contamination Zydus Pharmaceuticals USA Inc NDC 68382-916-34 D-1449-2019
Class II · Moderate risk

MethylPREDNISolone Tablets

CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

Terminated Cross-contamination Zydus Pharmaceuticals USA Inc NDC 68382-916-01 D-1448-2019

Recalls by year